Thymocartin

Thymic Peptide / Immunomodulatory PeptideRx: ResearchCompound: Research

Also known as: RKDV, Thymocartin, Thymopentin fragment 32-35, TP-4

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Thymocartin is a synthetic tetrapeptide (Arg-Lys-Asp-Val) corresponding to the active region of thymopoietin (residues 32–35). It was investigated as an immunostimulatory agent capable of inducing T-cell differentiation, with potential applications in immunodeficiency states and as an adjunct in oncology. It has not achieved broad clinical approval and remains largely a research compound.

Mechanism of Action

Thymocartin (TP-4) is a tetrapeptide fragment derived from thymopoietin that binds to T-lymphocyte precursors and promotes T-cell differentiation and maturation by modulating cAMP levels and lymphocyte surface marker expression.

Routes of Administration

IntramuscularIntravenousSubcutaneous

Goals & Uses

  • Autoimmune disease modulationImmunologyUnknown
  • Adjunctive cancer immunotherapyOncologyLow
  • Immunodeficiency treatmentImmunologyLow
  • T-cell immunomodulationImmunologyLow

Contraindications

  • Known hypersensitivity to thymocartin or thymopoietin derivativesAllergyHigh
  • Active autoimmune disease requiring immunosuppressionImmunologyModerate
  • Organ transplantation / immunosuppressive therapyTransplant MedicineModerate

Adverse Effects

  • Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
  • Injection site reactionsLocalCommon
  • HeadacheNeurologicUncommonPain in the head or upper neck
  • Fever / flu-like symptomsSystemicUncommon

Drug Interactions

  • Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
  • Other immunostimulatory agentsLow

Population Constraints

  • Patients with active malignancyOncologyRelative
  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative
  • Pregnant womenReproductiveRelative

Regulatory Status

  • European UnionInvestigationalInvestigated in European clinical research in the 1980s–1990s; no current EMA approval.
  • United StatesUnapprovedNot approved by FDA; no IND or NDA on public record for this compound.
  • United KingdomUnknownNo MHRA approval identified; considered a research compound.

Thymocartin has not received FDA, EMA, or MHRA approval as a marketed therapeutic. It has been investigated in clinical research primarily in European settings. No current approved indication is on record in major jurisdictions.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack